Difference between BABE study and clinical trials [Design Issues]

posted by dshah – India, 2020-07-31 08:46 (316 d 02:52 ago) – Posting: # 21813
Views: 1,649

Dear VijithRoy!
As rightly mentioned by Helmut, BABE studies are considered as Phase-I study. Generally the concept for generics to perform BABE study is to use the already available knowledge of Innovator for safety and efficacy.
Apart from BCS based biowaiver;
A- Parenteral (IV, IM, SC, IT) adm. as aqueous solution;
B- Solution for oral use,
C-Gas ,
D- Powder for reconstitution as a solution (Meeting above A or B)
E- Otic or ophthalmic or topical product prepared as an aqueous solution
and few other dosage forms can be considered for biowaiver where BE is self evident.
On the other hand, Q1/Q2/Q3 criteria may needs to be matched to Innovator (case to case basis).

Regards,
DShah

Complete thread:

Activity
 Admin contact
21,518 posts in 4,498 threads, 1,523 registered users;
online 8 (0 registered, 8 guests [including 7 identified bots]).
Forum time: Saturday 11:38 UTC (Europe/Vienna)

If I find 10,000 ways something won’t work, I haven’t failed.
I am not discouraged, because every wrong attempt discarded
is another step forward.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5